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Structural studies of macromolecular com-
plexes have produced extraordinary insights
into a wide variety of biological processes.
Unfortunately, as structural biologists pursue
larger and more challenging assemblies,
weakly stable and/or nonspecific interactions
can become significant roadblocks to structure
determination. We have developed a rapid and
effective pool-based screen, termed FASTDXL
(focused array screening technique for disulfide
X-linking), to produce and identify disulfide-
stabilized protein-nucleic acid assemblies. A
significant strength of FASTDXL is that it can
take advantage of prior structural knowledge
about molecular interactions, but does not
necessarily rely upon it. A detailed application
of the approach to the difficult problem of trap-
ping a bacterial primase-ssDNA complex is
described, validating the method as a route to-
ward obtaining diffracting crystals suitable for
structure determination.
Introduction
With the recent multitude of advances in computational
methods, crystal growth has become perhaps the most
significant bottleneck for modern structural studies. Nu-
merous approaches to facilitate crystallization are in place
for single proteins, including homolog screening, directed
surface mutagenesis, and the addition of stabilizing li-
gands (Vedadi et al., 2006; McPherson and Cudney,
2006); however, when attempting to image amacromolec-
ular complex, the affinity and specificity of interacting
components for one another can rapidly become the crit-
ical determinant of a project’s success. The complex may
dissociate if the interactions are too weak, whereas non-
specific interactions can introduce heterogeneity that
may complicate or entirely preclude structure determina-
tion. For these reasons, complexeswhose structures have
been determined crystallographically (for example, a tran-
scription factor bound to its recognition site) are typicallyStructure 15,highly specific and benefit from dissociation constants
better than 100 nM.
Unfortunately for structural biologists, many important
biological processes are mediated by macromolecular
interactions that are low affinity, transient, or both. In these
cases, steps must be undertaken to trap the complex in
a stable state that is also biologically meaningful. In some
instances, the biology or chemistry of a system may sug-
gest a method to achieve this goal, such as the use of
vanadate to covalently link a topoisomerase to a designed
DNA substrate (Davies and Hol, 2004). However, no such
tools exist for many systems, forcing researchers to rely
upon exhaustive searches or blind luck, with little to no
guarantee of success.
A few groups have recently made significant inroads to-
ward addressing these problems using disulfide-based
crosslinking (DXL) approaches. For example, Verdine
and colleagues have pioneered the use of modified
thiolated DNA bases with engineered surface cysteines
to stabilize protein-DNA complexes via Cys-Cys cross-
links (Figure 1A) (Verdine and Norman, 2003). This
approach results in a population of homogeneous, cova-
lently tethered complexes, a sample condition that signif-
icantly enhances crystallization propensity (Verdine and
Norman, 2003; Buck and Wells, 2005; He and Verdine,
2002; Huang et al., 1998; Banerjee et al., 2006; Fromme
et al., 2004; Banerjee and Verdine, 2006; Sarafianos
et al., 2002, 2003). Unfortunately, a complication intrinsic
to most DXL methods is that they rely upon intimate prior
structural knowledge of a related protein-DNA complex to
directly inform placement of both the cysteine and the
modified base. For systems with a paucity of structural
information, this limitation can significantly impede
progress.
Here we describe a rapid and effective pool-based
screen for generating disulfide-stabilized macromolecular
complexes that can take advantage of prior structural
knowledge, but does not rely upon it. We have dubbed
this method the focused array screening technique for
disulfide crosslinking, or FASTDXL. To validate FASTDXL
as an approach, we systematically screened several
hundred protein-DNA combinations in only a few months,
resulting in two structures of the weak and nonspecific
bacterial primase (DnaG) bound to a single-stranded
DNA template.773–780, July 2007 ª2007 Elsevier Ltd All rights reserved 773
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Ways & MeansFigure 1. Overview of the FASTDXL Method
(A) Standard DXL. Modification of a convertible base (O6-phenyl-dI) to its crosslinkable form (N6-thioalkyl-dA) and its tethering to an engineered
cysteine mutant upon binding.
(B) The FASTDXL approach. A pool of mutant proteins (blue), each containing a different single surface-exposed cysteine mutation (yellow triangles),
is mixed with individual biotin-tagged oligonucleotides containing a crosslinkable base (green rectangles with yellow triangles) in one of several
positions. Each pool may generate complexes that contain one or more cysteine mutants covalently linked to DNA through a disulfide bond (red
triangles). Complexes are isolated through a streptavidin pull-down and the protein components are completely digested to peptides using trypsi-
nolysis. A second streptavidin pull-down separates crosslinked from free peptides, and reduction of the disulfide releases the peptides into the
supernatant for subsequent identification by MALDI-TOF and tandem MS. Each of the identified peptides arises from the crosslinking of a single
cysteine point mutant and one modified oligonucleotide. Once identified, the mutant-oligonucleotide pair is an attractive target for scale-up purifica-
tion and crystallization.FASTDXL: Focused Array Screening Technique
for Disulfide Crosslinking
The principal strength of FASTDXL is that it provides a
pool-based approach to interrogate numerous potential
crosslinking combinations simultaneously, and selects
for the formation of stable complexes with a simple pull-
down assay. A general outline of the method is shown
in Figure 1B. If one has any prior knowledge of a putative
interaction surface, be it biochemical or structural, a series774 Structure 15, 773–780, July 2007 ª2007 Elsevier Ltd All riof surface cysteine point mutations should be chosen to
saturate this region and the surrounding area. In the ab-
sence of prior information, the experimenter may resort
to a more randomized ‘‘shotgun’’ mutagenesis approach,
targeting potentially surface-exposed amino acids. It is
important to note that, whether or not an interaction sur-
face is known, engineered cysteine positions generally
should not be chosen to replace highly conserved or func-
tionally important residues.ghts reserved
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a single pool by simply mixing the expression vectors of
each mutant and transforming en masse. The heteroge-
neousmutant pool is then purified as per the wild-type tar-
get, albeit without reducing agent, and individually mixed
with a series of biotin-tagged oligonucleotides containing
a single crosslinkable base in a unique location. The posi-
tion of this modified base may simply be stepped through
the sequence, or prior information may be incorporated to
guide placement of the modification.
After the mutant pool is mixed with each DNA, a primary
streptavidin pull-down is used to isolate any mutant-DNA
combinations capable of forming a stable complex. These
complexes are then completely trypsinized to yield both
free peptides and cysteine-containing peptides cross-
linked to the nucleic acid. A second streptavidin pull-
down is subsequently used to isolate the peptides derived
from stably crosslinking mutants, followed by reduction of
the disulfide and a third pull-down to purify the peptides
remaining in the supernatant. Matrix assisted laser de-
sorption/ionization-time of flight (MALDI-TOF) and tan-
dem mass spectrometry (MS/MS) are employed to iden-
tify which cysteine-containing tryptic fragments crosslink
to a given oligonucleotide, and thus which combinations
of mutant and DNA are worthy of further pursuit.
To affirm the practicality of the FASTDXL screen, we
chose to apply the method toward a complex of the bac-
terial primase DnaG and a single-stranded DNA template
or RNA-DNA heteroduplex product. DnaG is an extremely
stringent test case, as it has a Kd of 1–20 mM for its sub-
strate and binds nonspecifically to single-stranded DNA
in a highly salt-sensitive manner (Khopde et al., 2002). Us-
ing FASTDXL, we successfully identified 8 specific, stably
crosslinking protein-oligonucleotide complexes from a to-
tal of 320 distinct combinations of 16 mutant proteins and
20 modified substrates. We then translated two of these
positive hits into diffracting crystals, producing structures
for both forms that show clear density for nucleic acid. No-
tably, attempts to obtain similar uncrosslinked complexes
failed for 15 different protein-oligonucleotide targets at the
point of crystallization. In fact, the DnaG-ssDNA complex
we have successfully isolated and visualized through this
approach may be the least stable polymerase-DNA com-
plex solved by X-ray crystallography to date (Figure 2).
An Applied Example: DnaG Primase + ssDNA
Template
Protein Preparation
The bacterial primase is a modular protein comprising an
N-terminal regulatory zinc binding domain, a central RNA
polymerase domain, and a C-terminal helicase interaction
domain. Though the zinc binding domain is important
for full activity and the control of primer length, the RNA
polymerase domain is capable of unregulated strand syn-
thesis and binds ssDNA templates nearly as well as the
full-length enzyme (Corn et al., 2005).
Ideally, constructs screened by FASTDXL would be
free of cysteines, apart from the engineered mutation, to
prevent spurious crosslinking. At the very least, themutantStructure 15background should be ‘‘cysteine light,’’ such that as many
surface-exposed cysteines have been ablated as possi-
ble. However, in the case of DnaG, the zinc binding
domain contains several invariant cysteines involved in
coordinating a zinc ion. When unsure whether a wild-
type cysteine will interfere with formation of a complex,
a FASTDXL screen using the wild-type construct will
identify the minimal set of background cysteines that
crosslink nonspecifically to a DNA template and must
therefore be removed. For DnaG, this test revealed that
two cysteines within the zinc ligandingmotif are extremely
reactive, crosslinking strongly to every thiol-modified oli-
gonucleotide tested (data not shown). Such a lack of re-
gard for oligonucleotide identity is a hallmark of native
cysteines that likely need to be removed for effective
screening.
To overcome high crossreactivity of the zinc binding do-
main, mutagenesis and screening were next performed
with a construct encompassing the isolated RNApolymer-
ase domain. A set of 16 cysteine point mutations was in-
troduced to cover much of the area surrounding DnaG’s
active site. Sites were chosen based on prior hypotheses
for the orientation of DNA within the primase active site,
with a few sites placed semirandomly at distal surface
positions to decrease screening bias. All 16 mutant pro-
teins were fused to an N-terminal TEV protease-cleavable
hexahistidine tag (Corn et al., 2005; Kapust and Waugh,
2000), and expressed as a pool by combining every
expression plasmid in a single tube and transforming
BL21-codon+ cells with the mixture. The simplified ex-
pression of a composite protein pool allows all mutants
to be purified simultaneously using a standard two-
step nickel-column purification scheme. It is worth noting
that nonexpressing or completely insoluble mutants
are effectively removed from the screen at this stage, elim-
inating the need to individually test candidate proteins for
these properties. Nonetheless, the high sensitivity of
FASTDXL’s mass spectrometry-based detection allows
one to detect candidate mutants with nonideal solubility
Figure 2. Affinities of Representative Crystallographically
Observed Complexes between Polymerases and Nucleic
Acids Deposited in the Protein Data Bank
The affinity of DnaG for its single-stranded DNA substrate is nearly
three logs worse than the affinity of the Y family DinB homolog (Dbh)
or A family T7 gp5 DNA polymerase (T7 DNAP) for their primer/tem-
plate substrates (see the Supplemental References)., 773–780, July 2007 ª2007 Elsevier Ltd All rights reserved 775
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targets are considered in the screening process.
Preparation of Modified DNA
Several options are available for the preparation of cross-
linkable nucleic acids, but all must be prepared from con-
vertible base precursors. O6-phenyl-dI (convertible dA)
and O4-triazolyl-dU (convertible dC) yield major-groove
crosslinking groups, whereas 2F-dI (convertible dG) yields
a minor-groove crosslink (Xu et al., 1992; Ferentz and Ver-
dine, 1991; MacMillan and Verdine, 1991; Erlanson et al.,
1993). Mixed-phosphonate oligonucleotides may also be
utilized for backbone-based crosslinks, though the syn-
thesis of these nucleic acids is nonstandard (Banerjee
et al., 2006). Oligonucleotides containing convertible dA
or convertible dC are commercially available from synthe-
sis companies, such as Operon Biotechnologies andMid-
land Certified Reagent Company, or can be readily syn-
thesized by standard methods using the appropriate
phosphoramidites available from Glen Research. Con-
vertible dG is only available as the phosphoramidite and
requires special procedures for synthesis and conversion
(see Glen Research product description). Note that each
modifiable base may have a unique scheme, available
from the manufacturer, for cleavage/deprotection from
the synthesis support and/or alkanethiol modification.
When screening for crosslinking to DnaG, we utilized
a panel of ten deoxyoligonucleotides, each with a 50 biotin
handle and O6-phenyl-dI (convertible dA) at a unique po-
sition. The modified base was converted to the crosslink-
able form with a two-carbon linker (Figure 1) by resus-
pending the dried oligonucleotide overnight at 68C with
1 ml of the free amine of cystamine at 1 M concentration.
This reagent was prepared by dissolving commercially
available solid cystamine HCl (Sigma) in a minimal volume
of water and deprotonating with a strong base (NaOH to
approximately pH 12), which causes neutralized cyst-
amine to precipitate in aqueous solution. The reactive
cystamine free amine, a yellowish oil or solid that must
be stored under argon, is then recovered using chloroform
extraction.
After derivatization of the convertible oligonucleotide,
excess cystamine is removed with a NAP-10 desalting
column (Amersham Biosciences), eluting the DNA with
100 mM triethylammonium bicarbonate (TEAB) (pH 8.5).
After final purification with a C18 Sep-Pak column (Waters
Corporation) using a 100 mM TEAB wash and 25 mM
TEAB/30% acetonitrile elution, the crosslinkable oligo-
nucleotides are lyophilized, resuspended in argonated
water, and stored under argon. For screening purposes,
a portion of each of the tenmodified deoxyribonucleotides
was also annealed to a short complementary oligoribo-
nucleotide to yield an RNA-DNA heteroduplex with a 50
DNA overhang. Thus, a total of 20 unique substrates
was assayed in subsequent crosslinking trials.
Protein-DNA Crosslinking and Isolation
of Complexes
To begin the screening process, each derivatized oligo-
nucleotide is separately mixed with the purified mutant
pool to yield a 1:1 molar ratio of eachmutant to the nucleic776 Structure 15, 773–780, July 2007 ª2007 Elsevier Ltd All rigacid target. For example, if screening 16 point mutants,
each reaction should contain a 16:1 molar ratio of pro-
tein:DNA. This strategy allows different mutants to com-
pete with each other for DNA crosslinking groups. For
DnaG, the crosslinking reaction (50 ml) was performed
under low salt conditions to favor DNA binding, and at
relatively high pH, which favors disulfide exchange. The
use of more basic conditions is particularly useful when
the complex suffers from a very slow kon rate, but it is
not inherently necessary for the formation of a stable com-
plex (He and Verdine, 2002). After reacting for a fixed
period of time (between an hour at room temperature to
overnight at 4C for DnaG-DNA trials), disulfide exchange
is quenched by lowering the pH to%6.5 with buffer.
Streptavidin sepharose (Amersham, 300 nmol/ml) pull-
down of the biotin-tagged DNA (15 ml packed resin), fol-
lowed by thorough washing with a high salt buffer (e.g.,
500 mM NaCl, 20 mM HEPES [pH 6.5]), should yield free
DNA and crosslinked protein-DNA complexes in the pel-
let. This may be verified by a mock crosslinking reaction
using a noncrosslinkable nucleic acid or a cysteine-less
mutant background. The crosslinked complexes are di-
gested on-bead overnight at 4C–25C by resuspending
in 50 ml of 1:10 w/w trypsin:protein in the presence of
1 mM CaCl2 (to yield more efficient cleavage) and 20 mM
methyl methanethiosulfonate (to cap natively inaccessible
cysteines released by digestion). After proteolysis, the
trypsin is deactivated by boiling, and the resulting cross-
linked peptide-DNA fragments are isolated with a second
pull-down, using fresh streptavidin beads. The disulfide
between peptide and ssDNA may now be released
through the introduction of a reducing agent, such as
tris(2-carboxyethyl)phosphine (TCEP) or DTT (30min incu-
bation at room temperature with 50 mM DTT was used in
the case of DnaG). A final streptavidin pull-down will yield
free peptides in the supernatant, each derived from a sin-
gle mutant and containing a cysteine that crosslinked to
the nucleic acid. As with any pull-down experiment, care-
ful controls (such as the use of a cysteine-light protein or
a noncrosslinkable mock DNA) should be utilized to mini-
mize nonspecific adsorption to the beadmaterial and/or to
identify such peptides as false positives. Unwanted back-
ground arising from nonspecific interactions may be pre-
vented through standard methods, such as the inclusion
of a nonionic detergent in the crosslinking buffer/washes.
In the case of DnaG, 10% of the final pull-down super-
natant was removed before the addition of reducing agent
to provide a background control for identifying any disul-
fide-specific interactions.
Identification of Stable Protein-DNA Combinations
Once crosslinking and subsequent digestion reactions
have been performed, MALDI-TOF mass spectrometry is
used to identify which cysteine mutant(s) crosslinked to
each nucleic acid. For DnaG, 0.6 ml of matrix solution (a-
cyano-4-hydroxycinnamic acid in 50:50 acetonitrile:water
containing 0.1% TFA) was mixed on the target plate with
0.6 ml of sample solution and investigated with a 4700 Pro-
teomics analyzer (Applied Biosystems). Several distinct
peptide species were observed in the postreductionhts reserved
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Ways & MeansFigure 3. MALDI-TOF Mass Spectrum of
Peptides Isolated from a Typical Protein-
DNA Crosslinking Reaction
Background peptides (DTT) from before the
addition of reducing agent are shown (lower
gray trace). Peptides corresponding to disul-
fide-specific crosslinks (+DTT) are shown
above and in black. All labeled peptides were
positively identified by tandem mass spec-
trometry.supernatant (Figure 3). A few highly abundant peptides
were identified in both the pre- and postrelease samples,
and were subsequently identified as trypsin and streptavi-
din usingMS/MS tandemmass spectrometry. Against this
background, peptides corresponding precisely to the pre-
dicted mass of cysteine-containing tryptic fragments from
individual point mutants of DnaG were also identified, and
the sequence of these peptides was verified by MS/MS.
Each ssDNA or RNA-DNA heteroduplex yielded a unique
set of mutants and efficiencies, allowing for the rational
selection of scale-up combinations (Table 1).
Notably, most of the engineered DnaG mutants were
apparently either insoluble, unreactive, or located too far
away from any crosslinkable base positions, and thusStructure 1were not detected in any of the pull-downs. Others, such
as Asn232Cys and Glu235Cys, strongly crosslinked to
every oligonucleotide substrate tested, suggesting that
these mutants are either highly nonspecific and reactive,
or accessible to several different crosslinkable base
positions. Significantly, three mutants (Arg243Cys,
Arg320Cys, and Thr324Cys) exhibited strong specificity,
only crosslinking to ssDNA substrates when the modified
base lay near the 30 end. To investigate the nature of the
nonspecific and specific complexes, we chose to scale
up production of the three candidates Asn232Cys,
Glu235Cys, and Arg320Cys, each of which formed a disul-
fide linkagewith an ssDNAsubstrate containing amodified
base in the tenth position (oligonucleotide xl10).Table 1. Relative Crosslinking Efficiency of Each Cysteine Mutant with Every Crosslinkable ssDNA
Modified Base Position (50-30)
Mutant 1 2 3 4 5 6 7 8 9 10
N232C +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
E235C +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
T236C          
D237C          
R243C         ++ 
T287C          
S288C          
T290C          
A291C         
D292C         
R299C         
R320C          +++
T324C + + + + + + + ++ ++ ++
T348C  +  +      
Whereas the Asn232Cys and Glu235Cys mutants form disulfides independent of the placement of the modified base, only
Arg243Cys, Arg320Cys, and Thr324Cys form promising position-specific crosslinks.5, 773–780, July 2007 ª2007 Elsevier Ltd All rights reserved 777
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Ways & MeansFigure 4. Successful Scale-Up of ‘‘Hits’’ Obtained from the FASTDXL Screen
(A) A nonreducing SDS-polyacrylamide gel of the Arg320Cys mutant mixed 2:1 with oligo2 indicates that crosslinking is complete within 19 hr.
(B) Top panel: anion-exchange chromatography of the Arg320Cys + oligo2 crosslinking reaction separates free protein, free nucleic acid, and the
protein-DNA complex. A Bradford assay (dashed lines) was used to assay for protein, and an absorbance scan between 240 nm and 300 nm was
used to assay for nucleic acid. Bottom panel: size-exclusion chromatography of the isolated protein-DNA complex indicates a decreased retention
time compared to the apo protein, consistent with formation of a stable complex, and further separates free nucleic acid.
(C) Crystal forms obtained for two different mutant-oligonucleotide combinations. Asn232Cys + oligo1 forms extremely thin plates with a monoclinic
lattice that diffract anisotropically to 3.0 A˚, and Arg320Cys + oligo2 crystallizes in a hexagonal space group and diffracts cleanly to 2.4 A˚.Scale-Up, Purification, and Crystallization
Once stable complexes have been identified, each prom-
ising cysteine mutant can be individually expressed and
purified in the absence of reducing agent using the
methods described earlier. Crosslinked protein-DNA
complexes are then formed by 12–48 hr incubation of
a mutant with the appropriate derivatized oligonucleotide
lacking the original biotin tag. The use of a 2:1 molar ratio
of protein:DNA while forming these complexes allows one
to ensure nearly 100% crosslinking efficiency of the oligo-
nucleotide, as confirmed via gel shift using nonreducing
SDS-PAGE (Figure 4A). Successfully formed complexes
may be isolated from free protein with an anion-exchange
column, and a subsequent gel-filtration column removes
free nucleic acid (Figure 4B). As in any protein-DNA co-
crystallography experiment, the length and base composi-
tion of the original crosslinking substrate may need to be
altered to obtain well-diffracting crystals. After designing
ten such variants upon the original xl10 screening oligonu-
cleotide and ensuring that they formed stable complexes
with the mutants in question, crystal screens identified778 Structure 15, 773–780, July 2007 ª2007 Elsevier Ltd All rigtwo DNA-dependent crystal forms: one for the Asn232Cys
complex and another for the Arg320Cys complex
(Figure 4C). No crystals were found for the Asp235Cys
complex. Crystals of the Asn232Cys and Arg320Cys com-
plexes, respectively, diffract to 3.0 A˚ and 2.35 A˚ and show
clear density for ssDNA; the structures of these com-
plexes will be reported elsewhere (unpublished data).
Note that any structure obtained via a trapping strategy,
such as disulfide crosslinking, should be rigorously vali-
dated using orthogonal methods, such as chemical
footprinting or mutagenesis. We have verified that the
crosslinked DnaG-ssDNA complex is biologically relevant
using both 1H-15N HSQC NMR of an uncrosslinked com-
plex and functional studies of targeted mutants (unpub-
lished data).
Future Perspectives for FASTDXL
Prior to developing the FASTDXL approach, obtaining
a primase-DNA cocrystal structure had proven impossi-
ble. This bottleneck presumably arose from the intrinsic
low sequence specificity and poor affinity of primase for
DNA (Khopde et al., 2002; Corn et al., 2005). FASTDXLhts reserved
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three complexes identified from the crosslinking screen
readily produced crystals that diffracted to reasonable
resolution and yielded interpretable difference density
for DNA from molecular replacement maps (unpublished
data). This success stands in stark contrast to our previ-
ous efforts, which attempted to crystallize 15 different un-
crosslinked protein-DNA combinations. These samples
either did not crystallize, did not diffract, yielded crystals
without DNA, or produced crystals containing DNA but
without interpretable density for the nucleic acid.
Compared to previously employed disulfide crosslink-
ing strategies, where one or a few cysteine mutants are
screened against one or two oligonucleotides at a time
(He and Verdine, 2002; Huang et al., 1998), FASTDXL
has several advantages. First, simultaneously expressing
all mutants under consideration saves a significant
amount of time on protein purification. Second, mass
spectrometry-based detection is far more sensitive than
the traditional nonreducing gel-shift strategy, with the ad-
ditional benefit of providing a direct readout of the cross-
linking site. The use of mass spectrometry can unambigu-
ously identify even weakly crosslinking complexes,
allowing one to search for patterns of reactivity that may
influence future rounds of screening. Indeed, the high
throughput and sensitivity of FASTDXL may reveal cross-
linking ‘‘hot spots’’ that can provide novel insights into the
molecular orientation of a complex, even before its struc-
ture is solved. Finally, when testingmany different mutants
and/or types and sequences of oligonucleotides, combi-
natorial gel-based approaches quickly become over-
whelming. In contrast, FASTDXL simultaneously tests en-
sembles of oligonucleotide-mutant pairs, greatly reducing
the amount of work and time necessary to achieve results.
Because of its scalability and robust design, FASTDXL
can investigate 50 cysteine positions as easily as 5, and
only a single reaction is necessary per crosslinkable oligo-
nucleotide tested. To facilitate these high-throughput
applications, we have written a simple PERL script (see
the Supplemental Data available with this article online)
to search MALDI-TOF peak tables for peptides with
masses corresponding to those predicted to arise from
each mutant.
Using FASTDXL, we were able to screen 320 distinct
protein-DNA combinations (16 mutants with 20 different
oligonucleotides—10 ssDNA, 10 RNA-DNA hetero-
duplexes), in approximately 4 months. Most of this time
was consumed bymutagenesis and sequencing to gener-
ate appropriate mutants. The combinatorial efficiency of
FASTDXL also allowed us to assay a wide range of cross-
linking sites, including many that would not have other-
wise been considered worthy. Fortuitously, the relatively
high throughput and broad nature of the screen rescued
the project from what might have been unrecoverable
bias in the placement of cysteine mutations, as the struc-
ture of DnaG bound to ssDNA reveals that prior modeling
assumptions for the complex were incorrect (unpublished
data). Using a one-by-one screening approach, we might
have spent months or years individually testing unproduc-Structure 15,tive combinations, but FASTDXL’s MALDI-TOF pool-
based approach permitted us to saturate the area sur-
rounding the primase active site to efficiently investigate
many more mutant-oligonucleotide permutations.
The study of multicomponent interactions is a rapidly
growing and critical area of structural biology. Structures
of complexes between proteins and nucleic acids
have yielded extraordinary insight into a wide variety of
biological processes and are increasingly important for
understanding regulation and mechanism. Many such
endeavors can become undermined by the technically
overwhelming demands presented by low specificity
and/or weakly binding complexes. We anticipate that
FASTDXL, a general screen for specific disulfide-based
crosslinks, will make the examination of such systems
more tractable, accelerating the pace of structural studies
for this underrepresented class of interactions.
Supplemental Data
Supplemental Data include references for Figure 2, one table, and
a script to search MALDI-TOF peak tables for proteolytic fragments
originating from crosslinking cysteine mutants, and can be found
with this article online at http://www.structure.org/cgi/content/full/
15/7/773/DC1/.
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